Pseudorabies virus PRV strain with defects in gE, gC, and TK genes protects piglets against an emerging PRV variant

Running head: ATTENUATED STRAIN AGAINST PRV VARIANT

Jinxin Lin1,2, Zhaolong Li2*, Zhihua Feng1, Zhou Fang1, Jianghua Chen1, Wengzhi Chen1, Wangwang Liang1, Qi Chen1

1Fujian Key Laboratory of Innate Immune Biology, Fujian Normal University Qishan Campus, 8 Xuefu South Road, Shangjie Town, Minhou County, Fuzhou, Fujian Province, China, 350117
2Institute of Animal Husbandry and Veterinary Medicine, Fujian Academy of Agricultural Sciences, 100 Pudang Road, Xindian Town, Jin'an District, Fuzhou, Fujian Province, China, 350013

*Corresponding author: Zhaolong Li
Address: Institute of Animal Husbandry and Veterinary Medicine, Fujian Academy of Agricultural Sciences, No.100 Pudang Road, Xindian Town, Jin'an District, Fuzhou, Fujian Province, China, 350013

Fax number: +86-0591-87572396

Correspondence e-mail address: 497377512@qq.com

ABSTRACT

The prevalence of an emerging variant of the pseudorabies virus (PRV) has been causing serious losses to farmers in China. Moreover, the commercially available PRV vaccine often fails to provide thorough protection. Therefore, in this study, we generated a PRV-ΔgC\gEΔTK strain with defects in gC, gE, and TK of PRV. Compared to the parental PRV strain and the single gene deletion strains (PRV-ΔgC, PRV-ΔgE, and PRV-ΔTK), PRV-ΔgC\gEΔTK grew slowly, and exhibited fewer and smaller plaques on swine testis (ST) cells. Furthermore, animal experiment results showed that mice that were immunized intramuscularly with PRV-ΔgC\gEΔTK, survived throughout the experiment with no observed clinical symptoms, and were completely protected against PRV challenge. Additionally, deletion of the gC, gE, and TK genes significantly alleviated viral damage in the brain. Furthermore, one-day-old weaned piglets immunized intramuscularly with PRV-ΔgC\gEΔTK elicited higher levels of gB antibodies against both the emerging PRV variant and the parental PRV, exhibited full protection against challenge with both variants, and showed neutralization capacity against PRV. These data suggest that PRV-ΔgC\gEΔTK is a promising vaccine candidate for the control of pseudorabies.
KEYWORDS: gC/gE/TK deletion, PRV-ΔgC/ΔgEΔTK, pseudorabies virus, vaccine

INTRODUCTION

Pseudorabies virus (PRV) is a member of the genus Varicellovirus, belonging to the PRV family Alphaherpesvirinae, which can infect numerous livestock and wild animals, with swine being the natural viral reservoir [3, 24]. Infected pigs manifest various clinical symptoms, including nervous system disorders and high mortality in young piglets, respiratory disorders and growth retardation in mature pigs, and reproductive failure in sows. In the last decade, pseudorabies (PR) has been well-controlled in China, owing to the Bartha-K61 vaccine. However, since late 2011, PR has shown occurrences even in Bartha-K61-vaccinated pigs, particularly in those that were intensively inoculated. Recent evidence has further indicated that the Bartha-K61 live vaccine was incapable of providing sufficient protection against novel variants [2, 21, 22, 30]. Thus, Chinese farms urgently require the development of a novel vaccine to control the emerging PRV variant. At present, various vaccines have been reported, such as inactivated PRV (Fujian strain) and HB (Hubei strain) vaccines, as well as live attenuated vaccines of the HB-98 strain with a TK/gC double gene deletion, apart from SA215 strain (PRV) with a gE/gI/TK gene deletion, and HB2000 strain with a TK/gG/gE 3 gene deletion [2, 6, 12, 28]. However, these vaccines have been shown to be poorly effective at protecting pigs, according to recent clinical data, which revealed an average positive PRV rate of 8.27% between 2012 and 2017, indicating that PRV-vaccines currently used in China still show a high risk of PR prevalence [8, 10].
The PRV strain of Fa is the earliest isolated typical strain that caused PR prevalence in China, resulting in major economic losses for the pig industry [9]. Phylogenetic analysis has suggested that most of the newly isolated PRV strains in China in recent years originated from evolution of the PRV strain, some of which are very closely related, such as HuB-China-2016, GD-QY-2010, and GD-JM-2015 [10, 26]. Therefore, the PRV strain is suitable as a template for vaccine development. Previous reports have indicated that a gene-deficient strain derived from the PRV strain, SA215 (∆gE/gI-∆TK-), has high immunogenicity and long-term immunity, and was developed for use as a commercial live-attenuated vaccine [15, 17, 30]. Preliminary studies have shown that the transneuronal transfer function of gE and gI may be mediated by the formation of complexes; the absence of gE also affects gI function in vivo, thus making the deletion of gI unnecessary during vaccine development [4, 7, 16, 30]. However, the gC protein is a major virulent protein of PRV, involved in not only guiding the adsorption process between the virus and target cells, but also in nervous system invasion and release [18]. Previous sequence alignment results have identified many amino acid changes within gC proteins of the PRV circulating in China after the outbreak compared to those from the viruses prevalent in China before the outbreak. This indicates that these changes may also be associated with changes in the virulence of the virus [8]. Therefore, the PRV-vaccine with gC and TK deletion could potentially be developed into an effective commercial live-attenuated vaccine [8, 23].

In this study, we first constructed a live-attenuated PRV strain carrying deletions for
gC, gE, and TK using CRISPR technology, in vitro. The safety and immunological
efficacy of this strain, PRV-ΔgC\gEΔTK, were then evaluated. PRV-ΔgC\gEΔTK was
also compared with commercial vaccines generated from SA215 strains.

**MATERIALS AND METHODS**

*Plasmid construction and virus*

The stably expressing CRISPR/Cas9 plasmid system used in this study was
constructed by introducing sgRNA (targeting various genes and PRV genes) into a
lenti-CRISPR V2 plasmid (Addgene, Watertown, MA, USA) [4-5, 13, 19, 20, 25]. All
target sites and gRNA sequences used in this study are shown in Table 1. The
lenti-CRISPR V2 vector was cleaved with endonuclease Esp3I (BsmBI) (Thermo
Fisher Scientific, Waltham, MA, USA). The sgRNA was ligated into the vector using
T4 DNA ligase (Takara China, Dalian, China). The procedures for producing stably
expressing CRISPR/Cas9 plasmid systems were followed. PRV-Fa and PRV variants
(201715 strains) were isolated in 2017 from an infected pig farm in China, and
consequently propagated in Vero cells.

*Cell culture and transfection*

Both 293T and Swine testis (ST) cells were cultured in Dulbecco's modified Eagle
medium (DMEM) plus 10% FBS (GIBCO, Invitrogen, Carlsbad, CA, USA) at 37 °C
with 5% CO₂. Plasmids were transfected into cells using Lipofectamine 3,000
6

(Sigma, St. Louis, MO, USA) according to the manufacturer’s instructions. Briefly, 2
$10^5.0$ cells were cultured in a 35-mm cell culture dish in DMEM with 10% FBS
(GIBCO BRL USA, Grand Island, NY, USA), which was then replaced with
OPTI-MEM medium (GIBCO, Invitrogen) after reaching about 75% confluence.
Then, 7.5 $\mu l$ Lipofectamine 3,000 was added to 250 $\mu l$ OPTI-MEM
(GIBCO, Invitrogen, USA) medium and allowed to rest for 5 min, after which 2.5 $\mu g$
of the plasmid was added and gently shaken for 5 sec to allow for even distribution of
the plasmid in solution. After standing for 5 min, the mixture was slowly added
dropwise to a centrifuge tube containing Lipofectamine 3,000, gently shaken for 5 sec,
and then allowed to rest for 10 min before the mixture was transferred to cell culture
medium by pipetting. The cell culture dish was gently shaken to uniformly distribute
liposomes, and then the mixture was transferred to the cell incubator.

Production of Lentivirus

Next, $1 \times 10^6.0$ 293T cells were cultured in a 10-cm cell culture dish with 6 ml
DMEM plus 10% FBS. The mixture of lenti-CRISPR V2-gRNA, pCMV-VSV-G, and
pSPAX2 (4:3:2) totaling 22.5 $\mu g$ was gently mixed with 200 $\mu l$ OPTI-MEM in a
1.5-ml centrifuge tube, and 67.5 $\mu g$ polyetherimide (PEI) was mixed with 200 $\mu l$
OPTI-MEM culture broth in another 1.5 ml centrifuge tube (PEI:plasmid = 3:1). After
standing for 5 min, the plasmid mixture was added dropwise to the PEI mixture and
mixed by gentle shaking. After standing for 10 min at 25 °C, the mixture was
uniformly added to the culture medium. The cell culture dishes were gently shaken to evenly distribute liposomes in each dish. After transfection, the culture dish was placed in a cell incubator for 12 hr. The culture medium was then replaced and the dish was incubated for another 24 hr, after which the cell culture supernatant containing lentivirus was harvested. Then, 6 ml DMEM containing 10% FBS was added, and the cells were incubated again, for 24 hr. The supernatant was harvested at 4 °C, centrifuged at 1200 × g for 10 min, and filtered through a 0.45 μm filter. The lentivirus titers were determined and used for cell infection (1 × 10^7.0 PFU/ml).

Construction of the ST cells stably expressing the CRISPR/Cas9 system

One ml of the lentiviral solution (1 × 10^7.0 PFU/ml) was added to cultured swine testis (ST) cells when the cell confluence reached about 80%, and infection was repeated 4 times (24 hr per repetition). The cells were passaged for 4 generations and screened using puromycin (3 μg/ml) to obtain stable cell lines. The genomic DNA was isolated using a Takara MiniBEST Universal Genomic DNA Extraction Kit Ver. 5.0 (Takara China). The sgRNA in the host cell genome was determined using polymerase chain reaction (PCR) and sequencing, and Cas9 protein expression was verified using western blotting.

PRV infection
The ST cells stably expressing CRISPR/Cas9 were infected with PRV (1 × 10^{4.0} TCID50). The infected cells were collected when 80% cells showed obvious cytopathic effects (CPE). After three freezing and thawing cycles, genomic viral DNA was extracted from the infected cells, and then amplified by PCR using a series of primers and PRV target sequences (gC, gE, and TK). All editing sites were verified via sequencing.

DNA and primer sequences, polymerase chain reaction (PCR), sequencing, and Quantitative RT-PCR

All gene sequences and PRV obtained from NCBI were analyzed using BioEdit software, primers and DNA sequences were synthesized by Shanghai Sangon Biotech, China, and DNA sequencing was performed by Fujian BioSune Biotech, China (Tables 1 and 2). The various sgRNAs were designed using the online CRISPR Design Tool (http://crispr.mit.edu).

PCR was performed in 20 μl composed of 7.2 μl ddH2O, 10 μl PrimeSTAR® Max DNA Polymerase (Takara China,), 0.4 μl forward primer, 0.4 μl reverse primer, and 50–100 ng (2 μl) of the viral or cellular genomic template. The PCR protocol was performed as follows: pre-denaturing at 98 °C for 5 min followed by 35 cycles of denaturing at 98 °C for 30 sec, annealing at 58 °C for 30 sec, and extension at 72 °C for 1 min. Then, the reaction was extended at 72 °C for 10 min and ended at 4 °C. The resulting PCR products were gel-purified and used for further sequencing.

For RT-qPCR analysis, total RNA was extracted with TRIzol (Sigma) and reverse
transcription was performed using the PrimeScript™ RT Reagent Kit with gDNA Eraser (Takara China). The composition of q-PCR reagents is as follows: 10.0 µl TaqMan® fast Advanced Master Mix (2×), 1.0 µl 1×TaqMan® Assay primer/probe (20×), 2.0 µl 1× cDNA template, 7.0µl Nuclease-free water, with total volume per reaction amounting to 20 µl. The procedure was as follows: pre-denaturation at 95 °C for 30 sec followed by 40 cycles of denaturation at 95 °C for 30 sec, annealing at 56 °C for 30 sec, and extension at 72 °C for 30 sec. The protocol for the melting curve stage was as follows: 95 °C for 15 sec, 72−90 °C for 35 cycles and each cycle increased by 0.1 °C. PCR was performed on the ABI StepOnePlus fast Real-Time PCR system (Applied Biosystems, MA, USA), and the changes in expression were calculated using the 2−ΔΔCT method.

Western blot analysis

The cell samples were collected and lysed with a protein extraction buffer containing 150 mM NaCl, 10 mM Tris (pH 7.2), 5 mM ethylenediaminetetraacetic acid (EDTA), 0.1% Triton X-100, 5% glycerol, and 2% SDS. The total protein concentration was determined using Coomassie Plus (Pierce Co., Ltd., Florida, USA). Equal amounts of protein were electrophoresed on 10% Tricine-SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. The membranes were then blocked overnight at 4 °C using a blocking buffer. Next, hybridization was performed with the corresponding primary antibodies followed by IRDye 800CW secondary antibody (1:1000), and these were then visualized using the Odyssey CLx Western
Blot Detection System (LI-COR, Lincoln, Nebraska, USA). GAPDH expression was used as the endogenous control.

**Viral plaque purification**

Both the genetically modified and the original PRV strains (1 × 10^{3.0} TCID50) were inoculated into ST cell monolayers in 10 cm culture plates. After incubation for 4 hr at 37 °C, the cells were washed twice with PBS and cultured in DMEM plus 2% FBS. After obvious cytopathic effects were observed via a microscope, the monolayers were washed twice with PBS, and the individual plaques were obtained using pipette tips.

**Effects of mutated viruses in cells**

Plaque counting and measurement: The ST cell monolayers were infected with wild type and genetically modified viruses, including PRV, PRV-ΔgC, PRV-ΔTK, and PRV-ΔgCΔgEΔTK (1 × 10^{3.0} TCID50). After incubating for 4 hr at 37 °C, the cells were washed twice with PBS and cultured in DMEM with 2% FBS for 24 hr. The cell morphologies were observed under a microscope, and morphologies of each group were recorded in 6 fields of view. In each field, plaques were counted and measured. The total number, average number, and size of plaques are shown in Fig. 2.

Comparison of plaque size: In 6-well plates, 1 × 10^{6.0} cells, 2 ml DMEM plus 10% FBS, and 1 × 10^{3.0} TCID50 viral solution were added to each well. The viruses used
for ST cell infection included PRV, PRV-ΔgC, PRVΔTK, and PRVΔgC\gEΔTK (1 × 10^{3.0} TCID50). The control group did not contain any virus. We set up 4-time gradients at 12, 24, 36, and 48 hr; viruses were collected every 12 hr and the viral titers were determined. We used a phase-contrast microscope for continuous observation of the amplification of individual plaques to compare their infectious ability and acquire images. To obtain the plaque amplification curves, 1 × 10^{5.0} cells were cultured in DMEM plus 10% FBS to reach 80% confluence, and then infected with 1 × 10^{2.0} TCID50 viruses; culturing continued for 12–15 hr. The plaques were selected and imaged every 30 min.

Animal experiments and serum neutralizing test

Four-week-old BALB/c mice were divided into various groups (5 mice per group). To evaluate the 50% lethal dose (LD50), four groups of mice were infected with serial dilutions of the viruses (PRV, PRV-ΔgC, PRV-ΔTK, and PRV-ΔgC\gEΔTK). Three other groups of mice were vaccinated with different doses of PRV-ΔgC, PRV-ΔTK, and PRV-ΔgC\gEΔTK (5 mice per group) by administering 100 µl injection to the left hind leg. Fourteen days after immunization, the mice were challenged with 1 × 10^5 TCID50 PRV wild type strains.

Twenty-four piglets, free of PRV, PCV2, PRRSV, CSFV, and PPV, were randomly divided into 4 groups and vaccinated with DMEM, PRV-ΔgC\gEΔTK (1 × 10^{6.0} TCID50 once), PRV-ΔgC\gEΔTK (1 × 10^{6.0} TCID50 twice), or commercial SA215 vaccine (1 × 10^{6.0} TCID50); the indicated second doses were given after 7 days. At 28
days post-vaccination, the piglets were challenged with $1 \times 10^{5.0}$ TCID50 PRV and PRV variant (isolated in our lab in 2017). After the challenge, the pigs were observed for 21 days and scored twice daily for clinical signs of the disease.

The serum was collected at 28 days post first vaccination to determine seroconversion via ELISA. PRV-specific gB antibody was evaluated using a commercial ELISA kit, according to manufacturer’s directions (IDEXX, Westbrook, ME, USA), and the antibody titers were tested using the serum neutralizing test (SNT). In brief, anterior vena cava blood was collected from the pig and maintained at 37 ℃ for 1 hr. The serum was centrifuged at 5000 × g for 5 min for antibody detection, then inactivated at 56 ℃ for 30 min, and finally diluted with sterilized saline (our laboratory preparation). The same volume of 200 TCID50/0.2 ml viral solution (PRV) was then added to each dilution. After mixing and incubating at 37 ℃ for 1 hr, the virus–serum mixture was inoculated into Vero cells (with each dilution tested in 3 wells) followed by incubation at 37 ℃ for 2 hr. Then, the virus–serum mixture was replaced with RPMI 1640 medium containing 2 % FBS, 100 U/ml penicillin, and 100 g/ml streptomycin, and the culture was incubated at 37 ℃ under 5% CO₂. At the same time, control wells with serum and virus-positive were set up. The CPEs of the cells were recorded after 5 days of culture. The neutralizing antibody titer was calculated using the Reed–Muench method.

All animal experiments were conducted in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals and approved by the Fujian
Provincial Office for Managing Laboratory Animals, and were overseen by the Fujian Normal University Animal Care and Use Committee (ethics license number IACUC-2016Y0027).

Histopathology and immunohistochemistry analysis

To perform histopathological analysis, forty female BALB/c mice (8 per group) were subcutaneously inoculated with $10^{3.5}$ TCID50 PRV, PRV-$\Delta gC$, PRV-$\Delta TK$, and PRV-$\Delta gC\Delta gE\Delta TK$, while the control group mice were inoculated with DMEM. Two weeks later, the mice were sacrificed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals from the Research Ethics Committee, Fujian Normal University, Fuzhou, China. Then, the mice brain tissues were fixed with 4% paraformaldehyde solution at 25 °C for 24 hr, followed by embedding them in 30% sucrose according to previously described [30]. The brain tissues were cut into 9 μm sections using a microtome and stored in a refrigerator at −80 °C. The sections were removed and incubated at 25 °C for 15 min, and then washed 4 times with PBS. Tissue sections were then incubated for 10 min with PBS/Triton X-100 (0.3%) (Merck KGaA, Darmstadt, Germany), followed by 2 hr incubation with 2% bovine serum albumin in PBS. Sections were then incubated with mouse monoclonal antibodies against human β-tubulin (Abcam, Cambridge, MA, USA) overnight at 4 °C, washed 3 times with PBS, and further incubated with fluorescent-conjugated donkey anti-rabbit IgG secondary antibody (Thermo Scientific, Waltham, MA, USA) for 2 hr at 37 °C. To visualize the nuclei, sections were stained
with 4,6-diamino-2-phenylindole (DAPI; Merck & Co., NJ, USA) and treated with an autofluorescence eliminator reagent (Merck & Co.). Images were taken with a Zeiss fluorescence microscope (Zeiss & Co., Germany) and analyzed using the NIH Image software.

Statistical analysis

The significant differences in the animal experiments were analyzed using Tukey’s test and the GraphPad Prism (version 8.0.1) software (San Diego, CA, USA). Differences were considered statistically significant when $p < 0.05$.

RESULTS

Construction of stably expressed Cas9 and sgRNA

To establish stable expression of the CRISPR/Cas9 system, sgRNAs (Fig. 1a) targeting TK, gC, and gE genes were inserted into the lenti-CRISPR V2 plasmid under the U6 promoter. This plasmid, along with the PCMV-VSV-G and sPAX2 plasmids, was used to produce the recombinant lentivirus that was used to infect ST cells, followed by a puromycin screen. The stable expression of Cas9 protein was verified using PCR, sequencing, western blotting, and an anti-FLAG antibody (Fig. 1b).
Deletion of gE, TK, and gC in PRV by stable expression of Cas9 protein

Cells stably expressing Cas9 and viral sgRNAs were selected using their resistance to puromycin. Twelve hours after viral infection, the cells were collected and subjected to PCR and sequencing to determine whether the system was valid, based on overlapping peaks shown in the sequencing data. Then, 3 or 4 rounds of infection were conducted. In order to obtain pure mutant strains, we performed plaque screening, followed by PCR and sequencing verification (as described in the methods section). The mRNA level of gE, TK, and gC on the PRV-ΔgC\gEΔTK group was significantly lower than that of the wild type virus (Fig. 1-c). The plaque screening and sequencing data showed that gE, TK, and gC mutants were successfully isolated, with deletions of 5, 4, and 5 bp, respectively (Fig. 1 d).

Biological characterization of PRV-ΔTK, PRV-ΔgC, and PRV-ΔgC\gEΔTK

To further characterize the mutant viruses with deletions in the gE, TK, and gC genes, we selected 3 mutant viruses (PRV-ΔTK, PRV-ΔgC, PRV-ΔgC\gEΔTK) isolated from the plaque screening for further validation. The plaque morphologies of the above-mentioned mutant strains differed from those of the wild type viral strains when grown in ST cell monolayers, and the number and size of the mutant viral plaques were both significantly reduced as compared to that of the wild type PRV (Fig. 2-1a-b). Reduction in the plaque size of mutant strains became more apparent following longer growth times. These data strongly suggest that TK, gC, and gE genes play a critical role in PRV viral replication via an unknown mechanism.
PRV-ΔTK, PRV-ΔgC, and PRVΔgC\gEΔTK growth on ST cells

PRV-ΔTK, PRV-ΔgC, PRVΔgC\gEΔTK, and PRV were simultaneously inoculated into ST cell monolayers. The data showed that PRV-ΔTK, PRV-ΔgC, and PRV-ΔgC\gEΔTK grew at a slower rate than PRV Fa, while PRV-ΔgC\gEΔTK grew the slowest (Fig. 2-2a). However, over time, the growth gap between the strains gradually narrowed. At 12 and 24 hr post infection, PRV-ΔTK, PRV-ΔgC, and PRV-ΔgC\gEΔTK titers were significantly lower than those of PRV Fa, and there was no significant difference between them (PRV-ΔTK, PRV-ΔgC, and PRV-ΔgC\gEΔTK). At 36 hr, the titer of PRV-ΔgC was significantly ($p < 0.05$) higher than that of PRV-ΔTK and PRV-ΔgC\gEΔTK. After 48 hr of infection, PRV-ΔTK, PRV-ΔgC, and PRV-ΔgC\gEΔTK titers were consistent with those of PRV Fa (Fig. 2-2b). These data suggest that the strains with deleted genes possess a relatively sound proliferative ability for producing sufficient immunogenicity for further vaccine development.

The immediate early 180 (IE180) gene is the only IE gene of PRV, possessing the important role of viral replication processing. As long as the IE180 gene is transcribed and translated into the IE180 protein, transcription and replication of its downstream genes should be activated. Consequently, Fig. 2-3a-3b shows that the deletion of gC, gE, and TK significantly decreased the transcription of IE180 mRNA, while it was not entirely blocked. It was observed that PRV with gC, gE, and TK deletions grew slowly.
The safety and immunogenicity of PRV-∆TK, PRV-∆gC, and PRV-∆gC\gE∆TK in mice

Vaccine safety is a primary factor taken into consideration during vaccine development. Therefore, PRV-∆gC\gEΔTK was assessed for its safety as a vaccine candidate using mice. Given that the mutant PRV genes caused a decrease in the viral propagation capacity (see above), we characterized the virulence of these attenuated viral strains in infected mice. Previous studies have shown that mice could be used as an animal model to effectively address pathologic injury caused by acute PRV infection. The median lethal dose, LD50, represents viral virulence in virology, where a lower LD50 is indicative of increased toxicity. Here, mice were injected with different doses of PRV Fa, and the LD50 dose for PRV was $1 \times 10^{3.8}$ TCID50 (Fig. 3a). In contrast, when inoculated in mice, the attenuated mutant viruses had higher LD50 doses. The LD50 of PRV-∆gC was $1 \times 10^{4.3}$ TCID50, while those of PRV-∆gC\gEΔTK and PRV-∆TK were both greater than $1 \times 10^{6.0}$ TCID50 (Fig. 3b, c, d), showing a clear decrease in viral infectivity. These data suggest that the virulent effects of attenuated PRV were indeed weakened by the deletion of gC or TK and gE in PRV, through genetic editing.

To further test the protective effect of gene-deletion in viruses, mice were vaccinated with different doses of PRV-∆gC, PRV-∆TK, and PRV-∆gC\gEΔTK. At 28 days post-immunization, these mice were challenged with $1 \times 10^{5.0}$ TCID50 PRV. The data showed that vaccination with PRV-∆gC\gEΔTK ($1 \times 10^{6.25}$ TCID50) and PRV-∆TK ($1 \times 10^{6.25}$ TCID50) provided complete protection against infection by the PRV strain, and no severe PR symptoms were observed (Fig. 3 e, f, and g). In contrast,
mice in the control group displayed apparent symptoms, including anorexia and intense pruritus, which led to lesions due to scratching and self-mutilation. Nervous signs became more pronounced and lack of coordination ensued, eventually resulting in paralysis.

To verify the virulent effects, forty female BALB/c mice (8 per group) were subcutaneously inoculated with $10^{3.5}$ TCID50 PRV, PRV-ΔgC, PRV-ΔTK, and PRV-ΔgC\gEΔTK, while the control group mice were inoculated with DMEM. Two weeks later, the dead and surviving mice were subjected to histological analyses. In the PRV group, Purkinje cells between the molecular and granular layers were distributed over irregular, widely spaced intervals (Fig. 4a). Nerve microtubules in the superficial layer of the cerebellum suffered severe damage, as indicated by broken cytoarchitectures (Fig. 4b). Immunohistochemical analyses revealed severe pathological damage in the brain, such as obvious meningeal inflammation and neuronal loss with clear signs of apoptosis in the granular layer of the cerebellum, as indicated by TUNEL assays (Fig. 4c). However, in the PRV-ΔgC and PRV-ΔTK groups, the nerve microtubules in the superficial layer of the cerebellum suffered from little damage, as indicated by broken cytoarchitectures, while the PRV-ΔgC\gEΔTK and control groups showed no obvious damage to the cerebellar layer or neurons (Fig. 4a-c).

PRV-ΔgC\gEΔTK strains provide full protection in piglets
PRV is a member of the Alphaherpesvirinae subfamily, and its infection can lead to one of the most devastating infectious diseases in swine. To test the vaccinal and protective efficacy of the PRV-ΔgC\gEΔTK vaccine in pigs, serum samples were collected from animals 28 days post-challenge and tested for gB-specific antibodies using PRV antibody detection kits. The data showed that anti-gB antibody increased significantly in vaccinated (once and twice) piglets (Fig. 5a), and the neutralization titers of the vaccinated group were significantly higher than those of the control group against PRV \( (p < 0.001) \), and PRV-ΔgC\gEΔTK vaccinated group exhibited neutralization titers similar to SA215 against PRV (Fig. 5b).

At 28 days post-immunization, the pigs were challenged with \( 1 \times 10^{5.0} \) TCID50 PRV wild type and PRV variant strains. Three vaccinated groups showed similar symptoms of depression and reduced food intake. Additionally, no neurological signs were recognized in the three groups, and all piglets remained alive. Accordingly, pigs vaccinated with DMEM developed typical PR symptoms, such as high fever, depression, anorexia, respiratory distress, vomiting, and trembling, and three piglets died; each on the 2, 5, and 8 days post-vaccination. These results demonstrated that PRV-ΔgC\gEΔTK is a safe and effective candidate vaccine for pig herds.

**DISCUSSION**

Due to the prevalence of a novel variant of PRV in recent years, commercially available PRV vaccines, particularly the Bartha-K61 vaccine, did not provide highly effective protection, causing major losses to local farmers [2, 14, 30]. Therefore, the development of a live-attenuated vaccine for the PRV variant is currently crucial for
controlling PRV. In this study, we constructed and evaluated PRV-ΔgC\ΔgEΔTK as a live vaccine candidate.

A live vaccine candidate requires a balance of safety, immunogenicity, and broad protection. The PRV strain of Fa was the first to be reported in 2000 [4], leading to the prevalence of PR in China as well as major economic losses to the pig industry. However, phylogenetic analyses have suggested that most of the newly isolated PRV strains in China in recent years originated from evolution of the parental PRV strains, some of which are very closely related, such as HuB-China-2016, GD-QY-2010, and GD-JM-2015 [1, 6, 21, 27, 28]. Therefore, PRV Fa is a typical strain suitable as a template for vaccine development. Some previous reports have indicated that a gene-deficient strain derived from the PRV Fa strain, SA215 (gE/gI/TK⁻), which has high immunogenicity and long-term immunity, and was developed as a commercial live-attenuated vaccine, could afford adequate protection against various PRV strains [10, 26].

Genes crucial for virulence but inessential for replication are potential targets for PRV live vaccine development. It is known that gI/gE forms a complex and is responsible for neurotropism and reactivation. Therefore, most PRV vaccine candidates exhibit gI/gE deletion, which is most desirable for attenuation and differential diagnostic tests. In PRV Fa, the deletion of gE breaks the function of the gI/gE complex and may be safe enough for newborn piglets; therefore, gI deletion is worth considering [15, 17, 30]. In addition, gC and TK were also involved in the invasion of the nervous system, as gC can affect virus release, and TK is associated
with viral replication in non-dividing cells [29]. Therefore, gC deletion may be more necessary for the development of an attenuated vaccine. Our studies also confirmed that the plaque size and numbers reduced significantly with gC deletion compared to those with PRV Fa. In addition, the deletion of gC genes significantly alleviated viral damage to the brain, and LD50 was significantly upregulated, while IE180 mRNA was also significantly downregulated. The results indicated that deletion of gC will slow PRV replication and improve the safety of candidate vaccine development.

In this study, we also tested the safety of the attenuated virus in 4-week-old mice. Mice were injected with different doses of wild type PRV. The PRV LD50 dose was \(1 \times 10^{3.8}\) TCID50. In contrast, the LD50 of PRV-\(\Delta gC\) was \(1 \times 10^{4.35}\) TCID50, while those of PRV-\(\Delta gC\)\(\Delta gE\)\(\Delta TK\) and PRV-\(\Delta TK\) were greater than \(1 \times 10^{6.0}\) TCID50, showing a clear decrease in viral infectivity. These results suggest that PRV-\(\Delta gC\)\(\Delta gE\)\(\Delta TK\) is safe for mice. Furthermore, the virulence-weakening assay also indicated that the deletion of TK and gC in PRV clearly reduced cerebral lesions and particularly reduced the destruction of tubulins in the central nervous system. Thus, TK and gC may also be essential for the persistence of PRV in the neural tissues of mice [29]. We also showed that mortality rate was greatly reduced when mice were infected with a gC mutant strain (PRV-\(\Delta gC\)) than a wild type virus. Therefore, we believe that PRV-\(\Delta gC\)\(\Delta gE\)\(\Delta TK\) could be suitable for use as a candidate for vaccine production.

The efficacy evaluation demonstrated that a single inoculation of \(10^{5.25}\) TCID50 PRV-\(\Delta gC\)\(\Delta gE\)\(\Delta TK\) was capable of providing full protection to mice and pigs against
challenge with $10^{5.0}$ TCID50 PRV Fa. Conversely, in the DMEM-vaccinated group, no
mice survived after a challenge. This further demonstrated that immunization with the
gC, gE, and TK triple-gene-deletion strain with a lower TCID50 afforded sufficient
protection for the mice.

In growing pigs, the gB antibody generated by the commercial Bartha-K61
vaccine demonstrated a substantially lower protection against PRV, but the live
PRV-ΔgC\gEΔTK vaccine stimulated high levels of gB antibody against PRV, which
also elicited similar level of neutralizing antibody to SA215 strain [11]. These results
are consistent with previous reports that suggested that recent genomic comparisons
showed no significant genetic variation between PRV strains and PRV variants, and
all isolated PRV variants are highly homologous and clustered within the same
genotype as the PRV Fa strain. In summary, the newly developed PRV-ΔgC\gEΔTK
strain was validated as a vaccine candidate of PRV, and offered protection against
most variants in China.
ACKNOWLEDGMENTS

We would like to thank Shaoli Cai and Zhang Lin for administrative assistance, and the members of the Chen laboratory for technical assistance and helpful discussion.

REFERENCES

[1] A. M. Mulder, W., Priem, J., M. A. Pol, J. and Kimman, T. 1995. Role of viral proteins and concanavalin A in in vitro replication of pseudorabies virus in porcine peripheral blood mononuclear cells. J. Gen. Virol. 76 (Pt 6): 1433-1442.

[2] An, T.-Q., Peng, J.-M., Tian, Z.-J., Zhao, H.-Y., Li, N., Liu, Y.-M., Chen, J.-Z., Han, L., Sun, Y., Chang, D. and Tong, G.-Z. 2013. Pseudorabies Virus Variant in Bartha-K61-Vaccinated Pigs, China, 2012. Emerg. Infect. Dis. 19: 1749-1755.

[3] Card, J., E Whealy, M., Robbins, A. and Enquist, L. 1992. Pseudorabies virus envelope glycoprotein gI influences both neurotropism and virulence during infection of the rat visual system. J. Virol. 66: 3032-3041.

[4] C. Mettenleiter, T. 2000. Aujeszky’s disease (pseudorabies) virus: The virus and molecular pathogenesis - State of the art, June 1999. Vet. Res. 31: 99-115.
[5] Cong, L. and Zhang, F. 2015. Genome engineering using CRISPR-Cas9 system. *Methods Mol. Biol.* **1239**: 197-217.

[6] Dong, B., S Zarlenega, D. and Ren, X. 2014. An Overview of Live Attenuated Recombinant Pseudorabies Viruses for Use as Novel Vaccines. *J. Immunol. Res.* **2014**: 824630.

[7] E Whealy, M., Card, J., Robbins, A., R Dubin, J., Rziha, H. and Enquist, L. 1993. Specific pseudorabies virus infection of the rat visual system requires both gI and gp63 glycoproteins. *J. Virol.* **67**: 3786-3797.

[8] Ferrari, M., Brack, A., Romanelli, M., C. Mettenleiter, T. H., Corradi, A., Dal Mas, N., Marina Nadia, L., Silini, R., Pinoni, C. and Pratelli, A. 2001. A Study of the Ability of a TK-Negative and gI/gE-Negative Pseudorabies Virus (PRV) Mutant Inoculated by Different Routes to Protect Pigs Against PRV Infection. *J. Vet. Med. B. Infect. Dis. Vet. Public Health* **47**: 753-762.

[9] Gaoming, L., Jingqun, A., Lin, Y., Weixian, D. and Xunzhang, W. 2001. Cloning and sequencing of gE gene encoding area of pseudorabies virus PRV strain excluding signal peptide. *Chinese J. Vet. Sci.* **21**:1 568-570.

[10] Gu, J., Hu, D., Peng, T., Wang, Y., and Xiao, Y. 2018. Epidemiological investigation of pseudorabies in Shandong Province from 2013 to 2016. *Transbound Emerg Dis.* **65**: 890-898
[11] Guo, W. Z., Zhi-Wen, X. U., Wang, X. Y., Lu, C., Yin, W. and Wang, M. S. 2000. Construction of new generation Pseudorabies virus gene deleted vaccine and the study of biologic characteristics. *J. Sichuan Agric. Univ.* **01**(018): 1-10.

[12] Hu, D., Zhang, Z., Lv, L., Xiao, Y., Qu, Y., Ma, H., Niu, Y., Wang, G. and Liu, S. 2015. Outbreak of variant pseudorabies virus in Bartha-K61-vaccinated piglets in central Shandong Province, China. *J Vet Diagn Invest.* **27**:600-605.

[13] Jinek M, et al.2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science.* **337**(6096):816-821.

[14] Jin-Mei, Peng. 2013. Identification and antigenic variation of new epidemiology of pseudorabies virus from swine. *Chin. J. Preven. Vet. Medic* **35**:1-4.

[15] Jing, X. U., Wan-Zhu, G., and Long-Xing, W. 2009. Construction of the recombinant pseudorabies virus SA215(E) strain expressing E protein of Japanese encephalitis virus. *Chin.J.Vet.Sci.* **2**:182-186

[16] Lamote, J., Kestens, M., Waesberghe, C., Delva, J., De Pelsmaeker, S., Devriendt, B. and Favoreel, H. 2017. The Pseudorabies Virus Glycoprotein gE/gI Complex Suppresses Type I Interferon Production by Plasmacytoid Dendritic Cells. *J. Virol.* **91**: e02276-16.
[17] Ling, Z., Wan-zhu, G. and Zhi-en, X. 2004. Fluctuant rule of colostral antibodies and the date of initial immunization for the piglet from sows inoculated with pseudorabies virus gene-deleted vaccine SA215. *Chinese J. Vet. Sci.* **24**: 320-322.

[18] Maeda, K., Hayashi, S., Tanioka, Y., Matsumoto, Y. and Otsuka, H. 2002. Pseudorabies virus (PRV) is protected from complement attack by cellular factors and glycoprotein C (gC). *Virus Res.* **84**: 79-87.

[19] Mali, P., Yang, L., Esvelt, K., Aach, J., Güell, M., Dicarlo, J., E Norville, J. and Church, G. 2013. RNA-guided Human Genome Engineering via Cas9. *Science.* **339**(6121):823-826.

[20] Marceau, C., Puschnik, A., Majzoub, K., Ooi, Y. S., Brewer, S., Fuchs, G., Swaminathan, K., A. Mata, M., Elias, J., Sarnow, P. and Carette, J. 2016. Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. *Nature.* **535**:159-163.

[21] Müller, T., Hahn, E. C., Tottewitz, F., Kramer, M., Klupp, B. G., Mettenleiter, T. C. and Freuling, C. 2011. Pseudorabies virus in wild swine: A global perspective. *Arch. Virol.* **156**: 1691-1705.

[22] Molin, B. and Harrow, L. 2004. Evaluation of Rough Brucella Strains as Vaccines for Brucellosis and Pseudorabies in Swine.*04*:5-12
[23] Nakamichi, K. and Otsuka, H. 2000. Attachment and Penetration Properties of Bovine Herpesvirus 1 Recombinants Expressing Pseudorabies Virus Glycoproteins gC and gB. *Intervirology.* **43:** 87-94.

[24] Pomeranz, L., E Reynolds, A. and Hengartner, C. 2005. Molecular Biology of Pseudorabies Virus: Impact on Neurovirology and Veterinary Medicine. *Microbiol. Mol. Biol. Rev.* **69:** 462-500.

[25] Ramanan, V., Shlomai, A., Benjamin Turitz Cox, D., Schwartz, R., Michailidis, E., Bhatta, A., Arthur Scott, D., Zhang, F., M. Rice, C. and N. Bhatia, S. 2015. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. *Sci. Rep.* **5:** 10833.

[26] Sun, Y., Wan, L., Liu, Q., Zhao, T., Zhu, H., Hua, L., Peng, Z., Tang, X., Stratton, C., Zhou, D., Tian, Y., Chen, H. and Wu, B. 2018. Epidemiological and genetic characteristics of swine pseudorabies virus in mainland China between 2012 and 2017. *PeerJ.* **6:** e5785.

[27] Tao, H., Baoan, C., Yan, W., Mingfan, Y., Xuebin, W. and Sumei, Z. 2004. Cloning and sequence analysis of the TK gene of pseudorabies virus Min--A strain. *Acta Agric. Univ. Henanensis.* **38:** 111-115.

[28] Wang, J., Guo, R., Yongfeng, Q., Xu, M., Wang, Z., Liu, Y., Gu, Y., Liu, C. and Hou, J. 2016. An inactivated gE-deleted pseudorabies vaccine provides
complete clinical protection and reduces virus shedding against challenge by a Chinese pseudorabies variant. *BMC Vet. Res.* **12**(277):11-20.

[29] Weixing, F., Xuelian, Z., Hongkun, Z. and Puyan, C. 2002. Cloning, sequencing and structural evolution analysis of the thymidine kinase gene of a wild Chinese PRV LA strain. *Bing du xue bao = Chinese J. Virol.* **18**: 249-258.

[30] Wu, R., Bai, C., Sun, J., Chang, S. and Zhang, X. 2013. Emergence of virulent pseudorabies virus infection in Northern China. *J. Vet. Sci.* **14**:363-365.

[31] Yan, J., Yufeng, H. and Puyan, C. 2002. Construction of Transfer Plasmid Vector of gE-gI Gene Partial Deletion Mutant of Pseudorabies Virus SH Strain Including GFP Report Gene. *Nong ye sheng wu ji shu xue bao = J. Agric. Biotechnol.* **10**: 363-366.

[32] Zhu, L., Yi, Y., Xu, Z., Cheng, L., Tang, S. and Guo, W. 2011. Growth, physicochemical properties, and morphogenesis of Chinese wild-type PRV Fa and its gene-deleted mutant strain PRV SA215. *Virol. J.* **8**: 272-281.

**Figure Legends**

Figure 1. Identification of swine testis (ST) cell-Cas9+/sgRNA+ and virus knockout
strains. (a) Design of sgRNAs for targeting virulence-associated genes (TK, gC, gE) of PRV Fa. (b) Verification of Cas9 expression in the ST-Cas9/sgRNA system expressed in the host ST cells using western blotting. (c) The mRNA level of gC, gE, and TK of PRV-ΔgC\gEΔTK and PRV Fa. (d) Sequencing analyses confirming the presence of mutant gC, gE, and TK genes of PRV in host cells (*p < 0.05, **p < 0.01, ***p < 0.001, Tukey’s test).

Figure 2. Verification of the virulence of PRV, PRV-ΔgC, PRV-ΔTK, and PRV-ΔgC\gEΔTK at the cellular level. 1(a) Morphology of plaques in the ST cell monolayer. 1(b) The number of plaques in ST cell monolayers infected with PRV, PRV-ΔgC, PRV-ΔTK, and PRV-ΔgC\gEΔTK. 2(a) Plaque morphologies present in ST cell monolayers infected with PRV, PRV-ΔgC, PRV-ΔTK, and PRV-ΔgC\gEΔTK viruses. 2(b) The titers of PRV, PRV-ΔgC, PRV-ΔTK, and PRV-ΔgC\gEΔTK viruses in different infection times. 3 (a, b) PRV IE180 relative expression level and plaque morphologies after infection with PRV, PRV-ΔgC, PRV-ΔTK, and PRV-ΔgC\gEΔTK viruses. Statistical analyses were performed using Tukey’s test and the data are presented as mean ± SD (n = 6, *p < 0.05, **p < 0.01, ***p < 0.001). Data was processed using GraphPAD prism 8.0.1 and CorelDRAW12 software.

Figure 3. TCID50 and survival analyses in mice. (a) TCID50 of PRV-WT. (b) TCID50 of PRV-ΔgC. (c,d) PRV-ΔTK and PRV-ΔgC\gEΔTK did not result in death. (e-g) Survival analyses of mice challenged with PRV after vaccination with the indicated doses of various genetically modified viral strains, including PRV-ΔgC, PRV-ΔTK, or
Figure 4. Pathological changes in the brain caused by PRV, PRVΔgC, PRVΔTK, and PRV-ΔgC\gEΔTK in mice. (a) Pathological changes in the cerebella of mice caused by infection with PRV, PRVΔgC, PRV-ΔTK, or PRVΔgC\gEΔTK were observed using hematoxylin and eosin staining. (b) Tubulin distribution and morphology in mouse cerebella were observed using immunofluorescence. (c) Neuronal apoptosis in the cerebellar sections detected with TUNEL (TdT-mediated dUTP Nick-End Labeling). The enlarged area is indicated by yellow arrows, and the red bar represents 200 µm. Data was processed using CorelDRAW12 software.

Figure 5. Protective efficacy of attenuated live vaccines against PRV challenge in pigs. (a) Anti-PRV seroconversion in pigs before and after challenge. Sera were collected at 0 and 28 days post-vaccination. Commercial ELISA kits were used to test anti-PRV gB antibody. The S/N ratio was calculated as the sample OD450 divided by the negative control OD450. S/N < 0.6, positive; S/N between 0.6 and 0.7, inconclusive; S/N > 0.7, negative. (b) Neutralizing antibodies against PRV were tested in 96-well plates (*p < 0.05, *** p < 0.001) (a,b: Data was analyzed using Tukey’s test). (c) Survival rate with PRV challenge. (d) Survival rate with PRV variant challenge.

| sgRNA name | Sequence                  | Target locus   |
|------------|---------------------------|----------------|
| PRV-gE-F   | 5’-caecgGCCGGCGACGATGACCTCGA-3’ | 122841-122861  |
| PRV-gE-R   | 5’-aaacTCGAGGTCATCGTCGCCGGC-3’   |                |
Table 2 The primers for PCR, q-PCR, and sequencing

| Primer name   | Sequence                          | Product length |
|---------------|-----------------------------------|----------------|
| PRV-TK-F      | 5′-caccgTGCCGAGCGATGCGGTAC-3′     | 59515-59535    |
| PRV-TK-R      | 5′-aaacGTACGCCATCAGGCTCGGGAac-3′  |                |
| PRV-gC-F      | 5′-caccgTCGACCACGACGGGCTCGA-3′    | 96423-98443    |
| PRV-gC-R      | 5′-aaacTCGAGCGCCGTCGTTGCGGAac-3′  |                |
| PRV-gE-F      | 5′-AAAAGGTGGTGTGTTTGCATAATT-3′    | 2,697 bp       |
| PRV-gE-R      | 5′-TCGGTTGGTGATGATGAAACG-3′       |                |
| PRV-TK-F      | 5′-TCGTAGAAGCGGTTGTGG-3′          | 1,324 bp       |
| PRV-TK-R      | 5′-CGACCAGGACGAACAGG-3′           |                |
| PRV-gC-F      | 5′-ATGGCCTCGCTCGCGGCTCG-3′        | 1,464 bp       |
| PRV-gC-R      | 5′-CGCCGGGTCCCGCTGTA-3′           |                |
| PRV-gE-F      | 5′-TGCGCCGCGCTCGGCGGAG-3′         | 200 bp(q-PCR)  |
| PRV-gE-R      | 5′-CGCACCTTCGCCCCCGAGCAC-3′       |                |
| PRV-TK-F      | 5′-CGCGATACCCGCGGCGGCCGCG-3′      | 130 bp(q-PCR)  |
| PRV-TK-R      | 5′-TCATGCGGACGCGCCGCGG-3′         |                |
| PRV-gC-F      | 5′-CGAGACCGAGGGCGTCTACAC-3′       | 171 bp(q-PCR)  |
| PRV-gC-R      | 5′-GCCCATCATCAGCGCCCTGC-3′        |                |
| V2-sgRNA-F    | 5′-GTGAATAGATAGTTAGGCAGGGAT-3′    | 797 bp         |
| V2-sgRNA-R    | 5′-CCCACTTCTCGGGGACTG-3′          |                |
| ST-GAPDH-F    | 5′-GGTACGGATGAGCGGATTT-3′         | 245 bp         |
| ST-GAPDH-R    | 5′-ATTTGATGTTGCGGGAT-3′           |                |
| PRV-IE180-F   | 5′-AGGTCTTCTGCGTGCAT-3′           | 102 bp         |
| PRV-IE180-R   | 5′-ACATCGGGGACGCCAT-3′            |                |
Fa-gE
SgRNA-ST
GCCGGCGACGATGACCTCGAGTTTT

Fa-TK
SgRNA-ST
TGCCCAGCCGATGGCCTACGTTTT

Fa-gC
SgRNA-ST
CACGTGCACCACGACGGCGCTCGATTTTT

(a)

(b)

(c)

(d)

Fa-ΔgE  GCCGGCGACGATGACCTC-----AACGGCGACCTTC
Fa-ΔTK  TGCCCGAGCCGATGGC-----TGCGCAGCTCTGT
Fa-ΔgC  CACGTGCACCACG-----GCTCGACCTCATCTTA

Cas9-Flag
GAPDH
DMEM  lenti-V2  gE  gC  TK
